8-K: Applied Therapeutics Announces Positive Q2 Results and Regulatory Progress for Govorestat

Applied Therapeutics reported its second quarter 2024 financial results, highlighting regulatory advancements for govorestat in treating Classic Galactosemia and SORD Deficiency.

Summary

• Applied Therapeutics announced its financial results for the second quarter ended June 30, 2024, showing a net income of $2.9 million, or $0.02 per basic common share, compared to a net loss of $29.6 million in the same quarter of 2023.
• The company's cash and cash equivalents totaled $122.2 million as of June 30, 2024, a significant increase from $49.9 million at the end of 2023.
• Research and development expenses decreased to $10.0 million from $11.9 million year-over-year, while general and administrative expenses increased to $10.6 million from $5.3 million.
• The company is progressing with regulatory submissions for govorestat, with a PDUFA target action date of November 28, 2024, for Classic Galactosemia and an expected EMA decision in early Q1 2025.
• The FDA has tentatively scheduled an advisory committee meeting for October 9, 2024, to discuss the NDA for govorestat in Classic Galactosemia.
• Applied Therapeutics is also planning to submit an NDA for govorestat for SORD Deficiency under the Accelerated Approval Program in early Q1 2025.
• The company expects its current cash reserves to fund operations into 2026, with a potential extension from the sale of a Priority Review Voucher upon approval of govorestat for Galactosemia.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the company's improved financial results, regulatory progress, and positive clinical data. The company's alignment with the FDA and EMA, along with the potential for a Priority Review Voucher, further contribute to the positive outlook. However, the delay in the EMA decision and increased expenses temper the sentiment slightly.

Positives

• The company achieved a net income of $2.9 million in Q2 2024, a substantial turnaround from the previous year's loss.
• The company's cash position has significantly improved, providing a strong financial foundation.
• The company is making significant progress with regulatory submissions for govorestat, with key dates set for FDA and EMA decisions.
• The company has aligned with the FDA on a potential NDA submission for govorestat for SORD Deficiency under Accelerated Approval.
• The company's updated cognition data for govorestat showed a statistically significant improvement compared to placebo.
• The company's inclusion in the Russell 3000 Index is a positive indicator of market recognition.

Negatives

• General and administrative expenses increased significantly to $10.6 million, primarily due to increased legal, professional, and commercialization costs.
• The company reported a net loss of $0.13 per diluted common share for the quarter, despite a net income on a basic share basis.
• The EMA granted a 3-month extension to the Day 120 clock stop period for the MAA review, which could indicate potential issues or delays.

Risks

• The company's future success is heavily dependent on the regulatory approval of govorestat for both Classic Galactosemia and SORD Deficiency.
• There are risks associated with the FDA and EMA review processes, including potential delays or non-approval.
• The company's financial performance is subject to fluctuations in research and development expenses and general and administrative costs.
• The company's ability to commercialize govorestat successfully will depend on market acceptance and reimbursement.
• The company's cash runway is dependent on the sale of a Priority Review Voucher, which is not guaranteed.

Future Outlook

The company expects its current cash reserves to fund operations into 2026 and anticipates that the sale of a Priority Review Voucher (PRV) could substantially extend the company's cash runway. The company also plans to submit an NDA for govorestat for SORD Deficiency under Accelerated Approval in early Q1 2025.

Management Comments

• Momentum continues with our steady regulatory progress in Classic Galactosemia and SORD Deficiency, said Shoshana Shendelman, PhD, Founder and CEO of Applied Therapeutics.
• We are incredibly pleased to share our alignment with the Neurology Division of the FDA regarding a potential second NDA submission for govorestat for the treatment of SORD Deficiency.

Industry Context

This announcement highlights the company's progress in developing treatments for rare diseases, a growing area of focus in the biopharmaceutical industry. The regulatory advancements and positive clinical data position Applied Therapeutics as a key player in the rare disease space, particularly in the treatment of Galactosemia and SORD Deficiency. The company's focus on unmet medical needs aligns with broader industry trends towards personalized medicine and targeted therapies.

Comparison to Industry Standards

• Applied Therapeutics' progress with govorestat is notable compared to other companies developing treatments for rare metabolic diseases, such as BioMarin Pharmaceutical and Ultragenyx Pharmaceutical.
• The company's PDUFA target action date of November 28, 2024, for govorestat in Classic Galactosemia is a significant milestone, comparable to other companies seeking FDA approval for novel therapies.
• The company's alignment with the FDA on a potential NDA submission for govorestat for SORD Deficiency under Accelerated Approval is a positive development, similar to other companies utilizing expedited regulatory pathways.
• The reported improvement of 8 points on a standard cognition scale for govorestat is a strong clinical outcome, comparable to other successful clinical trials in the rare disease space.
• The company's cash position of $122.2 million is a solid financial foundation, similar to other clinical-stage biopharmaceutical companies with promising drug candidates.

Stakeholder Impact

• Shareholders will be positively impacted by the improved financial results and regulatory progress.
• Patients with Galactosemia and SORD Deficiency stand to benefit from the potential approval of govorestat.
• Employees may experience increased job security and opportunities due to the company's growth.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• The company will prepare for the FDA inspection.
• The company will participate in the FDA Genetic Metabolic Diseases Advisory Committee (GeMDAC) meeting on October 9, 2024.
• The company will continue to work with the EMA on the MAA review for govorestat for Classic Galactosemia.
• The company will hold a pre-NDA meeting with the FDA to discuss administrative aspects of the submission for govorestat for SORD Deficiency.
• The company plans to submit an NDA for govorestat for SORD Deficiency under Accelerated Approval in early Q1 2025.

Key Dates

Keywords

Govorestat, Galactosemia, SORD Deficiency, NDA, MAA, FDA, EMA, Priority Review Voucher, Accelerated Approval, Rare Diseases, Clinical Trials, Biopharmaceutical, Russell 3000 Index